Evidence map›Paper›PMID 41279179›Full record

ArticlebioRxiv : the preprint server for biology2025

Phagocytes as Plaque Catalysts: Human Macrophages Actively Generate Pathogenic Aβ42 Fibrils with Seeding and Cross-Seeding Potency.

Katerina Konstantoulea, Meine Ramakers, Sarah C Borrie, Dries T'syen, Daan Moechars, Malgorzata A Sliwinska, Brajabandhu Pradhan, Giulia Albertini, Grigoria Tsaka, Bert Houben and 8 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Katerina KonstantouleaVIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium.
Meine RamakersVIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium.
Sarah C BorrieVIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium.
Dries T'syenVIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium.
Daan MoecharsVIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium.
Malgorzata A SliwinskaVIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium.
Brajabandhu PradhanVIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium.
Giulia AlbertiniVIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium.
Grigoria TsakaVIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium.
Bert HoubenVIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium.
Mark FiersVIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium.
Maarten DewildeLaboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven; Leuven, Flemish Brabant, 3000, Belgium.ORCID 0000-0002-3138-281X
Dietmar Rudolf ThalKU Leuven, Leuven Brain Institute, 3000 Leuven, Belgium.ORCID 0000-0002-1036-1075
Michael WillemBiomedical Center (BMC), Biochemistry, Faculty of Medicine, LMU Munich, Munich, Germany.
Jonas J NeherBiomedical Center (BMC), Biochemistry, Faculty of Medicine, LMU Munich, Munich, Germany.ORCID 0000-0003-1346-8924
Bart De StrooperVIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium.ORCID 0000-0001-5455-5819
Frederic RousseauVIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium.ORCID 0000-0002-9189-7399
Joost SchymkowitzVIB Center for Brain and Disease Research, VIB, 3000 Leuven, Belgium.ORCID 0000-0003-2020-0168

Funding

Heterotypic amyloid interactions as modulators of selective cellular vulnerabilityR01AG079234 · NIA · FLANDERS INTERUNIV INST BIOTECHNOLOGY · PI Frederic Rousseau, Joost Schymkowitz · 2022 to 2026
$2.5M
NIA NIH HHS R01 AG079234
6 · The paper itself

Abstract

The prevailing view frames microglia and macrophages as guardians against amyloid beta (Aβ) accumulation in Alzheimer's disease (AD). Here, we overturn this paradigm by demonstrating that human phagocytic cells-including differentiated THP-1 macrophages and iPSC-derived microglia-are not merely passive responders but active producers of extracellular, seeding-competent Aβ42 fibrils, the amyloid species most strongly linked to parenchymal plaque formation and neurodegeneration. These cell-generated aggregates differ structurally and functionally from synthetic fibrils, exhibiting heightened seeding activity and the ability to cross-seed tau aggregation, a key driver of AD progression. Notably, Aβ42 fibril formation in this system requires active cellular processes and is exacerbated by loss of TREM2, a major AD risk gene. Transcriptomic profiling reveals an early inflammatory response resembling microglial states observed in human AD models, positioning this system as a tractable, human-relevant platform to dissect the interplay between Aβ aggregation, innate immunity, and genetic susceptibility. Our findings suggest that macrophages and microglia play a dual role in AD, acting both as responders and inadvertent catalysts of pathogenic amyloid formation, with implications for early therapeutic intervention.

Indexed as

Alzheimer’s diseaseAmyloid aggregationAmyloid beta (Aβ42)InflammationMicroglial responseNeurodegenerationn vitro modelSeeding activityTHP-1 macrophagesTREM2 dysfunction

Identifiers

PMID41279179
PMCPMC12632591

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.